ImmunoPrecise is recognized as a compliant member by the Office of Laboratory Animal Welfare (OLAW) of the Department of Health and Human Services (HHS), USA. The Public Health Service of the National Institutes of Health (NIH), an agency of the HHS, has awarded IPA with a 5-year Animal Welfare Assurance Number and has been issued a Statement of Compliance (Assurance) with Standards for Humane Care and Use of Laboratory Animals. The Assurance and Agreement are key documents in defining the relationship of US academic researchers, the Public Health Service and ImmunoPrecise.
ImmunoPrecise is a member of the Canadian Council on Animal Care. The Canadian Council on Animal Care (CCAC) program is based on guidelines and policies which give clear direction to institutional animal care and use programs. IPA’s voluntary membership in CCAC demonstrates our desire to practice the safest and most humane use of animals within our private, in-house animal care facility.
ImmunoPrecise is a member of the Better Business Bureau. The BBB’s services are based on the belief that a business community committed to ethical business practices, coupled with an educated and informed public, are the keys to an ethical marketplace. IPA’s membership in such an organization demonstrates our ethical business practices, long-standing and excellent service in the biotech industry and our dedication to providing the best possible antibody reagents and services. IPA’s BBB Certificate.
Grant Krafft, PhD
Chairman and Chief Science Officer
Acumen Pharmaceuticals, Inc.
“The ImmunoPrecise ‘rapid-prime’ antibody technology proved pivotal to Acumen’s success, enabling timely identification of the first ADDL selective monoclonal antibodies. Subsequent proof-of-concept studies with our Northwestern colleagues led to our successful Merck collaboration to develop effective therapeutic antibodies for Alzheimer’s disease.”
Douglas McAllister, Ph.D. – President
“A number of the monoclonal antibodies developed for us by ImmunoPrecise Antibodies Ltd. are currently in use by several of our commercial clients in their rapid, point of care tests for infectious disease detection. This speaks to the fact that these antibodies are of the strictest specificities and highest affinities available.”
Dr. R.Gorczynski, MD PhD, Professor
University Health Network, MaRS Centre, Toronto Medical Discovery Tower
“The monoclonal antibodies developed for us by ImmunoPrecise Antibodies Ltd. over the past 5-10 years have been instrumental in providing proof-of-concept data for our research, which in turn has excited considerable commercial interest. Their reagents have always been developed promptly, tested to have the strict specificities we requested, and to have the highest affinities available. We would never consider another company to approach for outsourcing our monoclonal development.”